Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 1.00 |
| ▸ | MAOA | P21397 | 12/20 | 1.00 |
| ▸ | MAOB | P27338 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239917 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL239916 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL239551 | 0.83 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL13263330 | 0.83 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL239552 | 0.83 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL16602319 | 0.82 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL238927 | 0.82 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL238928 | 0.82 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL237945 | 0.78 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL13263154 | 0.78 | KDM1A (1.00) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045456-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2016-02-18 | — | — | US | disclosed |
| US-8993808-B2 | Phenylcyclopropylamine derivatives and their medical use | ORYZON GENOMICS, S.A. (ES) | 2015-03-31 | — | — | US | disclosed |
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| WO-2010084160-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | KDM1A 1515/4885MAOA 80/4885MAOB 143/4885 |
| US-20160045456-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | KDM1A 1515/4885MAOA 80/4885MAOB 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.